Since June 2011, Dr. Harris has served as the Senior Vice President of Translational Medicine at Biogen Idec. Dr. Harris has served as the Director of the Advanced Technology Program at SAIC Frederick since 2007 and Chief Technology Officer for SAIC Frederick since 2008. Prior to ... holding these positions, he served as the President and Chief Executive Officer of Novasite Pharmaceuticals Inc. from January 2005 to September 2006. Prior to that, he served as Chief Executive Officer for Structural GenomiX, Inc., a drug discovery and development company focused on innovative cancer therapeutics from 2003 to 2004 and as its President and Chief Executive Officer from 1999 to 2003. Dr. Harris started his career in biotechnology in 1981 as a group leader in Molecular Biology at Celltech Group and from 1989 to 1993 was Director of Biotechnology at Glaxo Group Research in the U.K. From 1993 until 1999, Dr. Harris was Chief Scientific Officer and Vice President of Research and Development at Sequana Therapeutics Inc. in San Diego, which became Axys Pharmaceuticals, Inc. in 1998 and was subsequently acquired by Celera Genomics. During the past five years, Dr. Harris has served on the board of directors of Dendreon Corporationration and he currently serves on the boards of directors of Origen Therapeutics, Inc. and Gyrasol Technologies and is Chairman of the Scientific Advisory Board of Bionomics Inc. in Australia.

Agnieszka is currently a Staff Scientist and Laboratory Manager at TessArae, LLC in Sterling, VA, USA. She obtained her PhD at the University of Queensland in Australia in a field of biochemistry, and subsequently worked as a post-doctoral fellow at Queen's University of Belfast ... University of Queensland and Institute for Molecular Biosciences. Since 2005 until 2008 she held a continuing appointment as a lecturer in a School of Dentistry at the University of Queensland and established her own laboratory in area of functional genomics and metabonomics. She has over 10 years of experience in molecular biology, genetics, genomics, biochemistry, microbiology and metabonomics. In addition she has experience as a science writer. Recently Agnieszka served on the Council of the Australian Society for Biochemistry and Molecular Biology and is still active in the society. Currently she is working on novel diagnostic assays for infectious diseases using microarray re-sequencing technology.

Dr. Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc., which is a genetics discovery company with tools, information and strategies for determining the medical impact of genes and genetic variations. He is also the founder of SelectX Pharmaceuticals ... a drug discovery company, Retrotope, an anti-aging company, and DiThera, a biotherapeutic company. Dr. Cantor is professor emeritus of Biomedical Engineering and of Pharmacology and was the director of the Center for Advanced Biotechnology at Boston University. He is currently adjunct professor of Bioengineering at UC San Diego, adjunct professor of Molecular Biology at the Scripps Institute for Research, and distinguished adjunct professor of Physiology and Biophysics at UC Irvine. Prior to this, Dr. Cantor held positions in Chemistry and then in Genetics and Development at Columbia University and in Molecular Biology at the University of California at Berkeley. Cantor was educated in chemistry at Columbia College (AB) and at the University of California Berkeley (PhD). Dr. Cantor has been granted more than 60 US patents and, with Paul Schimmel, wrote a three-volume textbook on biophysical chemistry. He also co-authored the first textbook on Genomics titled 'The Science and Technology of the Human Genome Project'. In addition, he sits on the advisory boards of numerous national and international biotechnology firms, has published more than 450 peer-reviewed articles, and is a member of the U.S. National Academy of Sciences.

Dr. Taylors background is in biophysics, bioinformatics, computational biology and structural biology with emphasis on human genetics and translational medicine. She obtained her Ph.D. in Biophysics from the University of Michigan, Ann Arbor, and completed a postdoctoral ... fellowship at Pfizer in Ann Arbor. She had worked in the pharmaceutical industry at EMD-Serono, transitioning into clinical and basic research by moving to Harvard School of Public Health and then to clinical research at RWJ/Rutgers. She also served several years as the Program Director of the Graduate Program in Bioinformatics at Brandeis University, where she still occasionally teaches a course in Computational Systems Biology. Her main areas of research are in the development of mathematical and computational methods to better understand biological variation and the genetic contribution to disease, coupling clinical information with high-dimensional biomedical data from next-gen sequencing, microarray, PCR, and proteomics experiments. Some of her immediate research interests are in development of methods to better classify effects of genetic variation within interacting systems through effects in gene function and contributions to disease, developing mathematical genotype representations of variation in populations, and using machine-learning techniques to build classifiers in translational medicine research. Her scientific contributions were acknowledged with the rest of the Divisions research team at the 2010 ASRM meeting when the REI division received the ASRM Prize Paper Award, where her contribution was in building databases, systems and validated methods for high-throughput genotype analyses .

Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical ... institutions, such as Harvard, Yale, Johns Hopkins, and Stanford, RGI helps custom design personalized research projects for diseases so rare that no organization exists to help. Dr. Lin is also a medical school faculty member at the Washington University in St. Louis and led the computational analysis of the first ever exome sequenching studies for any human disease at Johns Hopkins. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, Washington Post, and the Huffington Post.

John Quackenbush received his PhD in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for ... Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute and two years at Stanford University working at the interface of genomics and computational biology. In 1997 he joined the faculty of The Institute for Genomic Research (TIGR) where his focus began to shift to understanding what was encoded within the human genome. Since joining the faculties of the Dana-Farber Cancer Institute and the Harvard School of Public Health in 2005, his work has focused on the use of genomic data to reconstruct the networks of genes that drive the development of diseases such as cancer and emphysema.

Pierre-Antoine Gourraud is a former student of the Ecole Normale Suprieure de Lyon in France. After receiving an M.P.H. from University Paris XIII in 2002, he got his Ph.D. in Immunogenetic Epidemiology and Public Health from Toulouse University in 2005. He relocated to the ... United States to do his postdoctoral research in Neuroimmunogenetics of multiple sclerosis at UCSF in 2009 and joined the UCSF faculty in 2011. Dr Gourraud has established numerous research collaborations with investigators from all over the world: He develops bioinformatics resources at the National Center for Biotechnology Information (Immunogenetics markers: HLA, KIR, Microsatellites). At UCSF, he performs new generation of MS genetic association studies using massive sequencing technologies in various genetic ancestry backgrounds and continues developing software dedicated to translational digital medicine. His recent efforts have focused on the MS Bioscreen, a tablet-based navigation-system that integrates multiple dimensions of patient information including clinical evolution, therapeutic treatments, brain imaging, genomics and biomarker data.

Dr. Shawn C. Baker is the Chief Science Officer and co-founder of AllSeq. Having received his Ph.D. at the University of California - Davis, he started his career as a Research Scientist at Illumina when it was a 15-person startup. After spending several years at the bench ... developing gene expression array products, he transitioned to Product Marketing where he led a team in charge of Illuminas Expression and Regulation sequencing portfolio. In 2013 Dr. Baker co-founded AllSeq, establishing the only true sequencing marketplace, matching researchers with service providers based on their needs.

Dr. Mauro is an Associate Professor in the Department of Neurobiology at the Scripps Research Institute in La Jolla, California. He is also a co-founder and lead scientist of Promosome, a biotechnology company focused on bioproduction enablement and DNA vaccines. In addition, Dr ... Mauro is a Senior Fellow in Experimental Neurobiology at the Neurosciences Institute in San Diego, California. Prior to moving to The Scripps Research Institute, Dr. Mauro received his Ph.D. at McGill University in Montreal, Quebec, and continued his studies as a postdoctoral fellow at The Rockefeller University in New York City. Dr. Mauro studies both fundamental and applied aspects of translational control mechanisms. His basic research is focused on understanding how eukaryotic mRNAs recruit ribosomes, how ribosomes subsequently locate initiation codons, and how ribosomes regulate the translation of specific subsets of mRNAs. Dr. Mauro's applied studies build on his basic research. These applied studies have led to the identification of Translational Enhancer Elements (TEEs) and the generation of synthetic translational enhancers.

Yue Wan received her B.Sc in Cell Biology and Biochemistry from the University of California, San Diego. She obtained her Ph.D in Cancer Biology Stanford University, California, USA, under the mentorship of Howard Y. Chang. During her PhD, she developed the first ... high-throughput method for probing RNA structures genome-wide. Yue is a recipient of the NSS-PhD scholarship from Agency for Science, Technology and Research (A*STAR) in Singapore. She is currently a GIS fellow in the Genome Institute of Singapore and a Society in Science- Branco Weiss Fellow. Yue is interested in studying functional RNA structures and understanding their roles in regulating cellular biology.